Introduction: Lung and bronchial neoplasms are among the most prevalent and lethal worldwide, with high incidence and mortality rates. COVID-19, in turn, had a profound global impact on public health by severely compromising the respiratory system, reaching pandemic status between 2020 and 2023. The epidemiological overlap of these conditions poses a significant challenge and warrants due attention. Objectives: To identify variations in adjusted mortality and incidence rates of bronchial and lung neoplasms across Brazilian regions between 2016 and 2023. Methods: This retrospective epidemiological study used the “Epidemiology and Morbidity” section of the DATASUS/TABNET platform to collect data on the resident population, number of cases, and to calculate incidence rates per 100,000 inhabitants. Adjusted mortality rates were obtained from the INCA Mortality Atlas. Filters applied included the years 2016 to 2023 and ICD-10 category C34 (Malignant neoplasm of bronchi and lungs). Microsoft Excel was used to tabulate the data and analyze variations over the years studied. Results: In the pre-pandemic period, the average incidence rate (IR) was 5.41, with the southern region presenting the highest rate (11.31) and the northern region the lowest (2.00). The average mortality rate in the same period was 15.29, again with the south leading (22.59) and the northeast recording the lowest rate (11.69). Between 2020 and 2023, the average IR rose by 29.02% compared to the pre-pandemic period, reaching 6.98. During this time, the south maintained the highest incidence (14.06), a 24.31% increase, while the north still had the lowest rate (3.27), albeit higher than previously. Conversely, mortality decreased slightly during the pandemic, averaging 14.15. Regional trends remained, with the south showing the highest mortality (20.78) and the northeast the lowest (11.06), representing decreases of 8.01% and 5.38%, respectively. Conclusion: The southern region consistently exhibited the highest incidence and mortality rates, potentially due to its greater industrial activity, contributing to air pollution and increased respiratory system aggression. During the pandemic, incidence rates tended to rise, while mortality slightly declined. This may reflect heightened health awareness and concern for respiratory symptoms, leading to earlier diagnoses and improved treatment outcomes, ultimately reducing mortality.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
